HAMAD MEDICAL CORPORATION

Novo Nordisk's Weight Loss Drug Wegovy Now Available in Qatar Through Ebn Sina Medical Partnership

20 days ago

• Ebn Sina Medical, an Aamal Company subsidiary, has partnered with Novo Nordisk to launch Wegovy (Semaglutide 2.4mg) in Qatar, addressing the country's high obesity rates of 41% among adults. • Wegovy, the first once-weekly GLP-1 receptor agonist for chronic weight management, has demonstrated an average 17% weight loss sustained over two years in clinical trials, with one-third of patients achieving at least 20% reduction. • The medication is available to Qatari patients through Hamad Medical Corporation coverage, while private market costs range from QR796 to QR1,909 monthly depending on dosage.

Brain Hemorrhage Treatment Market Expected to Grow Significantly by 2032 as AI Solutions Gain FDA Approval

2 months ago

• The brain hemorrhage treatment market is projected to experience substantial growth through 2032, driven by an aging population and increasing prevalence of risk factors such as hypertension and traumatic brain injuries. • Recent FDA approvals for AI-based diagnostic tools, including JLK-LVO and Heuron ICH, mark significant advancements in early detection and treatment of brain hemorrhages. • Several pharmaceutical companies including Baxter, Pfizer, and Novartis are developing promising pipeline therapies such as tissue plasminogen activator, alteplase, and BAF312 to address the significant unmet needs in brain hemorrhage treatment.

First-Ever RCT to Evaluate Human Albumin's Effectiveness in Aneurysmal Subarachnoid Hemorrhage Launches in Qatar

3 months ago

• Hamad General Hospital in Qatar initiates groundbreaking randomized controlled trial to assess human albumin's impact on clinical outcomes in aneurysmal subarachnoid hemorrhage patients. • The three-year study will enroll 84 patients to compare albumin-enhanced fluid management versus standard crystalloid therapy, focusing on reducing cerebral vasospasm and improving neurological outcomes. • The trial addresses a critical research gap, as aneurysmal subarachnoid hemorrhage affects working-age populations with up to 60% mortality rate in untreated cases.

Advancements in Traumatic Brain Injury Clinical Trials Highlighted for 2024

6 months ago

The latest report on Traumatic Brain Injury (TBI) clinical trials for 2024 showcases significant progress in developing novel therapies, with key companies and emerging drugs poised to impact the TBI market. The report emphasizes the importance of ongoing research and the potential of innovative treatments to improve patient outcomes.